香港股市 已收市

Kiora Pharmaceuticals, Inc. (7EY0.F)

Frankfurt - Frankfurt 延遲價格。貨幣為 EUR。
加入追蹤清單
0.5820+0.0530 (+10.02%)
收市:04:51PM CET

Kiora Pharmaceuticals, Inc.

332 Encinitas Boulevard
Suite 102
Encinitas, CA 92024
United States
858 224 9600
https://www.kiorapharma.com

版塊Healthcare
行業Biotechnology
全職員工

高階主管

名稱頭銜支付行使價出生年份
Dr. Brian M. Strem Ph.D.President, CEO & Director429.23k1980
Dr. Eric J. Daniels M.B.A., M.D.Chief Development Officer342.94k1974
Dr. Stefan Sperl Ph.D.Executive Vice President of CMC & Operations
截止 2022年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

公司管治

截至 無 止,Kiora Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。